功能性胃肠病病因新模型:免疫激活与低度炎症的作用
本文提出功能性胃肠病(包括肠易激综合征和功能性消化不良)的疾病模型,认为在遗传易感个体中,黏膜抗原暴露可引发肠道免疫激活和低度炎症,进而导致神经结构和功能改变,产生区域肠道高敏感和动力障碍。该模型可解释食物与感染相关性、症状重叠及女性优势等现象,未来管理可能转向基于客观病理的亚型分型及靶向治疗。
要点
- 功能性胃肠病可能并非无病理基础,免疫激活和低度炎症在部分亚型中已被发现。
- 抗原暴露(如微生物或食物蛋白)在遗传易感宿主中触发免疫激活,导致神经功能改变。
- 未来可能基于血清学、微生物学和临床评估进行客观病理亚型分型以指导靶向治疗。
核心结论
- 功能性胃肠病(IBS和FD)可能由遗传易感宿主中黏膜抗原暴露引发的肠道免疫激活和低度炎症所致,进而导致神经结构和功能改变。
研究设计与样本
- 本文为疾病模型提出类文章,基于现有证据提出功能性胃肠病的病理生理模型,未报告具体研究设计或样本量。
主要发现
- 在功能性消化不良(尤其是餐后不适综合征)和腹泻型肠易激综合征中已发现免疫激活及部分患者存在轻微肠道病理。
- 该模型可解释所有肠道和肠外症状、与食物和感染的关系、与胃食管反流病的重叠,以及女性优势和症状随时间波动。
临床怎么用
- 未来管理可能转向基于血清学、微生物学和临床评估的客观病理亚型分型,以确定何时在特定亚组中部署靶向治疗。
- 潜在靶向干预包括抑制免疫激活、阻断组胺等关键介质释放、针对特定微生物的治疗,以及基于体内客观检测后的饮食建议以消除相关食物抗原。
局限性
- 本文为提出的疾病模型,尚需进一步证据积累验证;未报告具体研究数据或样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic unexplained gastrointestinal symptoms impact more than 1 in 5 Americans and their families; these disorders include the irritable bowel syndrome (IBS) and functional dyspepsia (FD), currently classified by Rome IV as functional gastrointestinal disorders. By definition, IBS and FD have no established pathology, but emerging evidence suggests this paradigm may need revision. Immune activation and, in subsets, subtle intestinal pathology have been identified in FD (most notably, postprandial distress syndrome) and IBS-diarrhea. A disease model is proposed that accounts for all of the intestinal and extraintestinal symptoms, relationship to food and infection, and the overlap with gastroesophageal reflux disease. It is speculated that antigen presentation to the mucosa (e.g., microbial antigens or food proteins after acute gastroenteritis) induces, in a genetically primed host, immune activation of the intestine with low-grade intestinal inflammation and subsequently neuronal structural and functional alterations, producing regional intestinal hypersensitivity and motor dysfunction. Immune activation may explain the female predominance and fluctuations in immune activity for symptom variability over time. In the future, as further evidence accumulates, the management paradigm may potentially shift to objective pathology-based subtyping based on serological, microbiological, and clinical assessments to identify when targeted therapies should be deployed in subsets. Potential targeted interventions may include therapies to dampen down immune activation or block release of key mediators such as histamine, specific microbial targeted treatments that may reverse disease, and dietary advice to eliminate relevant food antigens after objective in vivo testing. Only by identifying causation can we eventually anticipate cure, and as the true pathology unravels in subsets, this may become a reality.
引用
- Talley NJ. What Causes Functional Gastrointestinal Disorders? A Proposed Disease Model. Am J Gastroenterol. 2020. PMID: 31895721. doi:10.14309/ajg.0000000000000485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。